echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Connoya IL-4Rα mAb Phase II clinical success

    Connoya IL-4Rα mAb Phase II clinical success

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: sunshine

    On March 30, Connoya announced that its Class 1 new drug CM310 has achieved all efficacy endpoints and obtained positive results in its Phase II clinical study (CM310NP001) for chronic rhinosinusitis with nasal polyps


    CM310 is an innovative humanized monoclonal antibody that targets human IL-4 receptor alpha subunit (IL-4Rα) independently developed by Connoya.


    Source: Connoya Prospectus

    CM310 is the first domestically produced IL-4Rα antibody approved by the State Food and Drug Administration for clinical trials.


    CM310NP001 is a multicenter, randomized, double-blind, placebo-controlled, multiple subcutaneous phase II clinical trial to evaluate the efficacy, safety, and pharmacokinetics of CM310 in patients with chronic sinusitis and nasal polyps science, pharmacodynamics, immunogenicity


    The results showed that the two primary efficacy endpoints were fully met.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.